Phase 3 ADVANCE OUTCOMES trial on ralinepag succeeds

Jul 29

1 min read

Patients with pulmonary arterial hypertension who took ralinepag in addition to their usual treatment were less likely to have their disease get worse than those who took a placebo. However, more people stopped taking ralinepag because of side effects.

Read the Lancet article

Recent Posts

Why men with systemic sclerosis-associated PAH fare worse

Men with systemic sclerosis and pulmonary arterial hypertension (PAH) tend to have more heart-related complications and lower survival rates. Differences in the effects of hormones such as estrogen an

First two patients enrolled in a clinical trial to treat Group 2 PH

A press release announced that the first two patients have enrolled in a trial of a treatment for Group 2 pulmonary hypertension (PH associated with left heart disease). The treatment procedure is min

Animal research shows miR-224 contributes to PAH

A small molecule called microRNA-224-5p (miR-224) appears to play an important role in the changes to the lung blood vessels that occur in pulmonary arterial hypertension (PAH). Researchers found that

Comments